A Dual Role for Death Receptor 5 in Regulating Cardiac Fibroblast Function
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Dual Role for Death Receptor 5 in Regulating Cardiac Fibroblast Function
Authors
Keywords
-
Journal
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-03
DOI
10.3389/fcvm.2021.699102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Dynamic Interplay Between Cardiac Inflammation and Fibrosis
- (2020) Toby P. Thomas et al. Frontiers in Physiology
- Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma
- (2019) Jong-Sung Park et al. Nature Communications
- Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation
- (2019) Miles A. Tanner et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling
- (2018) Laurel A. Grisanti et al. Theranostics
- Circulating proteins as predictors of incident heart failure in the elderly
- (2017) Markus Stenemo et al. EUROPEAN JOURNAL OF HEART FAILURE
- Noncanonical regulation of insulin-mediated ERK activation by phosphoinositide 3-kinase γ
- (2017) Maradumane L. Mohan et al. MOLECULAR BIOLOGY OF THE CELL
- GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction
- (2017) Emma Skau et al. European Journal of Preventive Cardiology
- Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection FractionCLINICAL PERSPECTIVE
- (2017) Camilla Hage et al. Circulation-Cardiovascular Genetics
- A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
- (2017) Lu Fang et al. Frontiers in Pharmacology
- Elevated Markers of Death Receptor-Activated Apoptosis are Associated with Increased Risk for Development of Diabetes and Cardiovascular Disease
- (2017) Ingrid Yao Mattisson et al. EBioMedicine
- Cardiac Fibrosis
- (2016) Joshua G. Travers et al. CIRCULATION RESEARCH
- Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study
- (2016) Romina di Giuseppe et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death
- (2016) Roslyn N. Crowder et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β2-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury
- (2016) Laurel A. Grisanti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
- (2016) Stella Bernardi et al. Biomed Research International
- Cardiac Fibroblast Glycogen Synthase Kinase-3β Regulates Ventricular Remodeling and Dysfunction in Ischemic Heart
- (2014) Hind Lal et al. CIRCULATION
- Resident fibroblast lineages mediate pressure overload–induced cardiac fibrosis
- (2014) Thomas Moore-Morris et al. JOURNAL OF CLINICAL INVESTIGATION
- β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt
- (2014) Laurel A. Grisanti et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
- (2013) K Azijli et al. CELL DEATH AND DIFFERENTIATION
- Isoproterenol effects evaluated in heart slices of human and rat in comparison to rat heart in vivo
- (2013) Julia E. Herrmann et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
- (2013) M van Dijk et al. Cell Death & Disease
- Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial
- (2010) Ragnhild Røysland et al. AMERICAN HEART JOURNAL
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β
- (2010) Polakit Teekakirikul et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of apoptosis markers in advanced heart failure patients
- (2009) A. Niessner et al. EUROPEAN HEART JOURNAL
- TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2
- (2008) U. Vilimanovich et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8
- (2008) Larisa L. Belyanskaya et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started